T.A. Sciences® has invested over $5 million in the acquisition of technologies and related patent rights that offer the potential to greatly expand the company’s portfolio of product offerings
T.A. Sciences® is dedicated exclusively to creating research-based, clinically tested wellness products that help address telomere shortening through the science of Telomerase Activation. Built upon a foundation strongly grounded in scientific evidence, T.A. Sciences® is widely recognized as the leader in the field of Telomere Biology.
In addition to spending over $1 million last year for leading edge, scientific research on Telomere Biology, T.A. Sciences® invested another $5 million on the acquisition of technologies and related patent rights that offer the potential to greatly expand the company's portfolio of product offerings.
Studies have shown that telomere length in dog breeds correlates to lifespan, a result consistent with findings in humans. However, unlike humans, dogs lose telemetric DNA 10 times as fast making them relatively short–lived.
A 2012 study published in the journal Cell Reports2 tested 15 breeds of dog and found that breeds like Beagles, Golden retrievers, Labrador retrievers and Miniature poodles, which have long telomeres compared to others, also live longer.
Dog owners view their pets as another member of the family and they want to take steps to improve their health span too. Anecdotally, T.A. Sciences® has heard of owners giving their dogs TA-65® products, which is why the company decided to include canine testing in its research plan. 125 dogs of various breeds were studied to develop safe formulation and dosing criteria.
Please check back here for updates on this and other exciting developments.
In addition to its forthcoming product for dogs,
T.A. Sciences® is also in the process of creating a formulation of
TA-65® for horses
Please check back here for updates on this and other exciting
T.A. Sciences® is working to develop U.S. Food and Drug Administration (FDA) approved therapeutic drugs. While the company has focused on the nutritional supplement market since its founding in 2002, it has always operated at a higher standard than the norms for the industry. T.A. Sciences® conducts extensive safety and efficacy studies on both animals and humans that are far beyond the level found in most supplement companies. This commitment to a research based, clinically tested approach has made T.A. Sciences® a recognized leader in bringing Telomere Biology to the marketplace. Thus, it was only natural for the company to expand into developing therapeutic drugs for treating diseases associated with aging.
In 2012 T.A. Sciences® acquired the worldwide rights to a new patent-pending compound that has the potential to prevent or treat many diseases associated with aging.
This exciting drug candidate has already undergone various enabling studies required by the U.S. Food and Drug Administration (FDA) to file an Investigational New Drug
T.A. Sciences® 2019 research plan includes funding to continue this promising project.
It is the company’s intention to develop products that can address many diseases associated
Therapeutic drugs utilizing the patented compound will require full FDA approval before
they can be sold to the public. It will take many years and much more investment before
T.A. Sciences® will possibly introduce an FDA-approved drug.
Please check back here for more updates on our progress in developing therapeutic drugs.